Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending June 30, 2014. The report serves as a notification of transactions involving directors, persons discharging managerial responsibility, or connected persons, rather than a financial performance report.
Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This document is strictly a regulatory disclosure regarding a change in director shareholdings.
Material Changes
The only material change disclosed is a transaction involving Dr. Moncef Slaoui, a Director of the Company. On June 27, 2014, Dr. Slaoui transferred the following shares to his former wife for nil consideration as part of a divorce settlement:
- 26,411 Ordinary Shares
- 32,926 American Depositary Shares
The Company and Dr. Slaoui were advised of this transaction on June 30, 2014.
Guidance, Outlook, and Risks
The filing contains no management commentary, financial guidance, outlook, risks, contingencies, or unusual items related to the company's operations or financial health.
Key Facts for Investor Verification
- Verify the impact of the share transfer on Dr. Slaoui's remaining beneficial ownership.
- Confirm that the transaction was executed for nil consideration in accordance with the divorce settlement.
- Note that this filing does not contain financial results for the period ending June 30, 2014.